Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim about mortality risk reduction in MoCD Type A is directly supported by the provided FDA label excerpts in Section 1 (indication) and Section 14 (overall survival with hazard ratio).
Category Scores
Accurate Statements
NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
Supported by Section 1 INDICATIONS AND USAGE: “NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.”
Clinical study evidence shows improved overall survival and includes a hazard ratio for risk of death of 0.18 (95% CI: 0.04, 0.72).
Supported by Section 14 CLINICAL STUDIES (Overall Survival): “Hazard Ratio for Risk of Death (95% CI): 0.18 (0.04, 0.72)”.
The mortality risk reduction claim for MoCD Type A is supported and not contradicted by the provided label excerpts.
Consistent with Section 1 (indication) and Section 14 (overall survival hazard ratio) excerpts provided.
Unsupported Statements
Contradictions
Important Omissions
No evaluation was provided for dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, or adverse reactions because the AI response focused only on the mortality-risk-reduction claim.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated mortality-risk-reduction claim is directly supported by the label indication and overall survival efficacy data provided; no dosing/safety instructions were asserted beyond label-supported indication/evidence.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Scope-limited evaluation: the response assessed only the mortality-risk-reduction claim and did not cover other label sections (dosing/safety/contraindications).
Suggested Improvement
If a broader label alignment audit is intended, explicitly evaluate and cite additional relevant sections (e.g., dosage/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring).